Asston Pharmaceuticals Launches Landmark IPO

Asston Pharmaceuticals, based in Navi Mumbai, launches its IPO on July 09, 2025, aiming to raise ₹27.56 Crores. Funds will bolster capital expenditure, debt repayment, and corporate growth. The issue follows a 100% book-building process, with shares listed on BSE SME platform. Revenue for FY25 was ₹2,503.92 Lakhs.

Mumbai (Maharashtra) [India], July 7: Asston Pharmaceuticals, headquartered in Navi Mumbai, will open its IPO on July 09, 2025, targeting a ₹27.56 Crore issue on the BSE SME platform.

The IPO, utilizing a 100% book-building process as per SEBI guidelines, allocates shares among QIBs, non-institutional investors, and retail individuals. Funds will enhance capital expenditure, manage working capital, repay debts, and support general corporate aims.

Dr. Ashish Narayan Sakalkar, Managing Director, emphasized the IPO as a major growth step, citing plans for infrastructure investments and expanding their presence in the pharmaceutical sector. FY25 saw the company record ₹2,503.92 Lakhs in revenue, showcasing its financial resilience.